News
Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...
If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
14h
Investor's Business Daily on MSNAvidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover DealAvidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with ...
Sarepta Therapeutics hired a Trump-connected lobbying firm after the death of a teenage boy treated with its Duchenne ...
Dr Vinay Prasad was asked to step down as the FDA's top vaccine official following several controversies during his brief tenure.
All living organisms' genetic information is stored in DNA, which is transcribed into RNA, which is translated into proteins ...
I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The ...
The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.
A 12-year-old boy from Carthage, Tennessee finds joy in his power wheelchair. His family are hoping for a cure for his muscular disease, Duchenne.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results